Business Description
Regenxbio Inc
NAICS : 325412
SIC : 2836
ISIN : US75901B1070
Total Employee Number:
371Description
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.12 | |||||
Equity-to-Asset | 0.06 | |||||
Debt-to-Equity | 3.37 | |||||
Debt-to-EBITDA | -0.31 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.17 | |||||
Beneish M-Score | -3.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.2 | |||||
3-Year EBITDA Growth Rate | 23 | |||||
3-Year EPS without NRI Growth Rate | 15.5 | |||||
3-Year FCF Growth Rate | 23.7 | |||||
3-Year Book Growth Rate | -44.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.46 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.58 | |||||
9-Day RSI | 67.27 | |||||
14-Day RSI | 69.72 | |||||
3-1 Month Momentum % | -30.34 | |||||
6-1 Month Momentum % | -57.98 | |||||
12-1 Month Momentum % | -32.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.62 | |||||
Quick Ratio | 2.62 | |||||
Cash Ratio | 2.12 | |||||
Days Sales Outstanding | 3.04 | |||||
Days Payable | 275.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.5 | |||||
Shareholder Yield % | 0.84 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.19 | |||||
Operating Margin % | -292.28 | |||||
Net Margin % | -330.23 | |||||
EBITDA Margin % | -261.15 | |||||
FCF Margin % | -269.18 | |||||
OCF Margin % | -266.2 | |||||
ROE % | -187.55 | |||||
ROA % | -60.62 | |||||
ROIC % | -102.98 | |||||
3-Year ROIIC % | -41.59 | |||||
ROC (Joel Greenblatt) % | -156.19 | |||||
ROCE % | -66.11 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.19 | |||||
PB Ratio | 34.02 | |||||
Price-to-Tangible-Book | 34.02 | |||||
EV-to-EBIT | -2.62 | |||||
EV-to-Forward-EBIT | 4.69 | |||||
EV-to-EBITDA | -2.8 | |||||
EV-to-Forward-EBITDA | 4.23 | |||||
EV-to-Revenue | 7.31 | |||||
EV-to-Forward-Revenue | 3.26 | |||||
EV-to-FCF | -2.71 | |||||
Price-to-GF-Value | 0.96 | |||||
Price-to-Median-PS-Value | 0.88 | |||||
Earnings Yield (Greenblatt) % | -38.17 | |||||
FCF Yield % | -32.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RGNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Regenxbio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 87.822 | ||
| EPS (TTM) ($) | -5.6 | ||
| Beta | 1.1757 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.15 | ||
| Volatility % | 89.3 | ||
| 14-Day RSI | 69.72 | ||
| 14-Day ATR ($) | 1.1184 | ||
| 20-Day SMA ($) | 10.8605 | ||
| 12-1 Month Momentum % | -32.34 | ||
| 52-Week Range ($) | 5.455 - 16.19 | ||
| Shares Outstanding (Mil) | 51.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regenxbio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regenxbio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:00 | In 28 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 27 days | ||
| General meeting for 2026 | 2026-05-29 09:00 | 6.89 (+3.92%) | ||
| Guidance call for 2026 | 2026-05-26 09:30 | 6.35 (-5.65%) | ||
| Guidance call for 2026 | 2026-05-20 09:30 | 5.66 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 08:00 | 10.04 (-0.30%) | ||
| REGENXBIO: Topline Results from Pivotal Trial of RGX-202 | 2026-05-14 08:00 | 10.04 (-0.30%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 10.04 (-0.30%) |
Show
Entries
Regenxbio Inc Frequently Asked Questions
What is Regenxbio Inc(RGNX)'s stock price today?
The current price of RGNX is $13.95. The 52 week high of RGNX is $16.19 and 52 week low is $5.46.
When is next earnings date of Regenxbio Inc(RGNX)?
The next earnings date of Regenxbio Inc(RGNX) is 2026-08-07 Est..
Does Regenxbio Inc(RGNX) pay dividends? If so, how much?
Regenxbio Inc(RGNX) does not pay dividend.
Guru Commentaries on NAS:RGNX
No articles.
Press Release
Articles on Regenxbio Inc
Headlines
See More- 1
Jun 22, 2026
RGNX gains sharply after report of FDA turnaround on rare-disease treatment
Seeking Alpha ā¢ 5:55am
Jun 17, 2026
Regenxbio, Replimune among gainers after FDA U-turn on UniQure
Seeking Alpha ā¢ 1:35pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers